<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581553</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-501</org_study_id>
    <nct_id>NCT02581553</nct_id>
  </id_info>
  <brief_title>Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Relative Bioavailability of Lesinurad/Allopurinol Fixed Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets and the Effect of Food on the Pharmacokinetics of Lesinurad/Allopurinol Fixed Dose Combination Tablets in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess relative bioavailability of lesinurad/allopurinol fixed dose
      combination (FDC), its individual components and the effect of food.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises 2 parts. Part 1 will assess the relative BA of lesinurad/allopurinol FDC
      and monocomponents in fasted subjects. Part 2 will assess the effect of food on the PK of FDC
      tablets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) endpoints in terms of maximum observed concentration (Cmax) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets</measure>
    <time_frame>Days 1 and Day 8</time_frame>
    <description>Cmax is the maximum observed concentration of a drug after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoints in terms of time of occurrence of maximum observed concentration (tmax) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Tmax is the time of occurrence of cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoints in terms of area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint (AUC last) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoints in terms of area under the plasma concentration time curve from and from zero to infinity (AUC 0-∞) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>AUC 0-∞ is a meausre of total concentration from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoints in terms of apparent terminal half-life (t1/2) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>t1/2 is a measure of apparent terminal half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events in terms of changes in laboratory parameters</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events in terms of electrocardiogram parameters</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events in terms of vital signs</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events in terms of physical examination findings</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence EF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesinurad/allopurinol 200/300 FDC tablets</intervention_name>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
    <arm_group_label>Sequence CD</arm_group_label>
    <arm_group_label>Sequence DC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesinurad 200 mg</intervention_name>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
    <arm_group_label>Sequence EF</arm_group_label>
    <arm_group_label>Sequence FE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol 300 mg</intervention_name>
    <arm_group_label>Sequence AB</arm_group_label>
    <arm_group_label>Sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesinurad/allopurinol 200/200 FDC tablets</intervention_name>
    <arm_group_label>Sequence EF</arm_group_label>
    <arm_group_label>Sequence FE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol 200 mg</intervention_name>
    <arm_group_label>Sequence EF</arm_group_label>
    <arm_group_label>Sequence FE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index ranging between 18 kg/m2 and 40 kg/m2.

          -  Screening serum urate level is ≤ 7.0 mg/dL.

        Exclusion Criteria:

          -  Asian subject who has a positive test for the HLA-B*5801 allele.

          -  History or suspicion of kidney stones.

          -  Estimated creatinine clearance, as determined at Screening, of &lt; 90 mL/min calculated
             by the Cockcroft-Gault formula using ideal body weight.

          -  Undergone major surgery within 3 months prior to Screening.

          -  Donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior
             to Day 1or has given a plasma donation within 4 weeks prior to Day 1.

          -  Inadequate venous access or unsuitable veins for repeated venipuncture.

          -  Received any strong or moderate enzyme-inducing drug or product within 2 months prior
             to Screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. Bhakta</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 26, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

